Currently, Onxeo is running a triple combination Phase Ib study (n=6; AsiDNA plus carboplatin plus paclitaxel). Top line results should be available by end-2020, subject to the COVID-19 pandemic impact. A major expansion of the R&D programme is the new Phase Ib/II REVOCAN trial. This new study will evaluate AsiDNA’s potentially unique ability to reverse tumour resistance to the PARP inhibitor, niraparib. First data are expected by the end of 2020 or early-2021. The outcomes of these
27 May 2020
Onxeo - Expanding AsiDNA R&D programme
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Onxeo - Expanding AsiDNA R&D programme
Valerio Therapeutics (ALVIO:PAR) | 0 0 0.0%
- Published:
27 May 2020 -
Author:
Dr Jonas Peciulis -
Pages:
9
Currently, Onxeo is running a triple combination Phase Ib study (n=6; AsiDNA plus carboplatin plus paclitaxel). Top line results should be available by end-2020, subject to the COVID-19 pandemic impact. A major expansion of the R&D programme is the new Phase Ib/II REVOCAN trial. This new study will evaluate AsiDNA’s potentially unique ability to reverse tumour resistance to the PARP inhibitor, niraparib. First data are expected by the end of 2020 or early-2021. The outcomes of these